TIANJIN DEV (00882) Subsidiary Lisheng Pharmaceutical (002393) Reports FY2025 Net Profit Surge of 126.72%

Bulletin Express03-10

Tianjin Development Holdings Limited (TIANJIN DEV, 00882) announced that its 34.12%-owned subsidiary, Tianjin Lisheng Pharmaceutical Co., Ltd. (002393), released unaudited preliminary results for the financial year ended 31 December 2025 on the Shenzhen Stock Exchange. Key highlights are as follows:

• Revenue reached RMB 1.39 billion, a year-on-year rise of 4.23%, driven by broader market coverage and higher product sales.

• Operating profit doubled to RMB 469.96 million, up 112.03%, supported by improved sales mix and dividend income from an equity instrument.

• Total profit climbed 111.36% to RMB 456.43 million.

• Net profit attributable to shareholders jumped 126.72% to RMB 418.37 million; basic earnings per share increased accordingly from RMB 0.72 to RMB 1.62.

• Excluding extraordinary items, attributable net profit rose 64.16% to RMB 169.08 million.

• Weighted average return on equity improved to 8.56% from 3.74%.

Balance-sheet metrics show a contraction largely linked to fair-value movements in equity holdings:

• Total assets declined 3.48% to RMB 5.58 billion.

• Owners’ equity attributable to shareholders fell 2.93% to RMB 4.63 billion, translating into net assets per share of RMB 17.98, versus RMB 18.50 at the beginning of the period.

Management attributes the robust profit growth mainly to stronger sales performance and dividend contributions, while marking-to-market adjustments on equity investments weighed on net asset values. The figures are preliminary and subject to audit; final results will be disclosed in Lisheng Pharmaceutical’s 2025 annual report.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1135591771?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-10 06:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1135591771","market":"hk","top_or_hot":-1,"title":"TIANJIN DEV (00882) Subsidiary Lisheng Pharmaceutical (002393) Reports FY2025 Net Profit Surge of 126.72%","media":"Bulletin Express","content":"<p>Tianjin Development Holdings Limited (TIANJIN DEV, 00882) announced that its 34.12%-owned subsidiary, Tianjin Lisheng Pharmaceutical Co., Ltd. (002393), released unaudited preliminary results for the financial year ended 31 December 2025 on the Shenzhen Stock Exchange. Key highlights are as follows:</p>\n<p>• Revenue reached RMB 1.39 billion, a year-on-year rise of 4.23%, driven by broader market coverage and higher product sales.</p>\n<p>• Operating profit doubled to RMB 469.96 million, up 112.03%, supported by improved sales mix and dividend income from an equity instrument.</p>\n<p>• Total profit climbed 111.36% to RMB 456.43 million.</p>\n<p>• Net profit attributable to shareholders jumped 126.72% to RMB 418.37 million; basic earnings per share increased accordingly from RMB 0.72 to RMB 1.62.</p>\n<p>• Excluding extraordinary items, attributable net profit rose 64.16% to RMB 169.08 million.</p>\n<p>• Weighted average return on equity improved to 8.56% from 3.74%.</p>\n<p>Balance-sheet metrics show a contraction largely linked to fair-value movements in equity holdings:</p>\n<p>• Total assets declined 3.48% to RMB 5.58 billion.</p>\n<p>• Owners’ equity attributable to shareholders fell 2.93% to RMB 4.63 billion, translating into net assets per share of RMB 17.98, versus RMB 18.50 at the beginning of the period.</p>\n<p>Management attributes the robust profit growth mainly to stronger sales performance and dividend contributions, while marking-to-market adjustments on equity investments weighed on net asset values. The figures are preliminary and subject to audit; final results will be disclosed in Lisheng Pharmaceutical’s 2025 annual report.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TIANJIN DEV (00882) Subsidiary Lisheng Pharmaceutical (002393) Reports FY2025 Net Profit Surge of 126.72%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTIANJIN DEV (00882) Subsidiary Lisheng Pharmaceutical (002393) Reports FY2025 Net Profit Surge of 126.72%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-10 06:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Tianjin Development Holdings Limited (TIANJIN DEV, 00882) announced that its 34.12%-owned subsidiary, Tianjin Lisheng Pharmaceutical Co., Ltd. (002393), released unaudited preliminary results for the financial year ended 31 December 2025 on the Shenzhen Stock Exchange. Key highlights are as follows:</p>\n<p>• Revenue reached RMB 1.39 billion, a year-on-year rise of 4.23%, driven by broader market coverage and higher product sales.</p>\n<p>• Operating profit doubled to RMB 469.96 million, up 112.03%, supported by improved sales mix and dividend income from an equity instrument.</p>\n<p>• Total profit climbed 111.36% to RMB 456.43 million.</p>\n<p>• Net profit attributable to shareholders jumped 126.72% to RMB 418.37 million; basic earnings per share increased accordingly from RMB 0.72 to RMB 1.62.</p>\n<p>• Excluding extraordinary items, attributable net profit rose 64.16% to RMB 169.08 million.</p>\n<p>• Weighted average return on equity improved to 8.56% from 3.74%.</p>\n<p>Balance-sheet metrics show a contraction largely linked to fair-value movements in equity holdings:</p>\n<p>• Total assets declined 3.48% to RMB 5.58 billion.</p>\n<p>• Owners’ equity attributable to shareholders fell 2.93% to RMB 4.63 billion, translating into net assets per share of RMB 17.98, versus RMB 18.50 at the beginning of the period.</p>\n<p>Management attributes the robust profit growth mainly to stronger sales performance and dividend contributions, while marking-to-market adjustments on equity investments weighed on net asset values. The figures are preliminary and subject to audit; final results will be disclosed in Lisheng Pharmaceutical’s 2025 annual report.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"00882","symbol_name":"天津发展","start_time":0,"source_url":"","article_id":"1135591771","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1135591771","pubTimestamp":1773094972,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Tianjin Development Holdings Limited (TIANJIN DEV, 00882) announced that its 34.12%-owned subsidiary, Tianjin Lisheng Pharmaceutical Co., Ltd. (002393), released unaudited preliminary results for the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"00882":"天津发展"},"translate_title":"天津DEV(00882)子公司力生制药(002393)报告2025财年净利润激增126.72%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00882":1},"content_text":"Tianjin Development Holdings Limited (TIANJIN DEV, 00882) announced that its 34.12%-owned subsidiary, Tianjin Lisheng Pharmaceutical Co., Ltd. (002393), released unaudited preliminary results for the financial year ended 31 December 2025 on the Shenzhen Stock Exchange. Key highlights are as follows:\n• Revenue reached RMB 1.39 billion, a year-on-year rise of 4.23%, driven by broader market coverage and higher product sales.\n• Operating profit doubled to RMB 469.96 million, up 112.03%, supported by improved sales mix and dividend income from an equity instrument.\n• Total profit climbed 111.36% to RMB 456.43 million.\n• Net profit attributable to shareholders jumped 126.72% to RMB 418.37 million; basic earnings per share increased accordingly from RMB 0.72 to RMB 1.62.\n• Excluding extraordinary items, attributable net profit rose 64.16% to RMB 169.08 million.\n• Weighted average return on equity improved to 8.56% from 3.74%.\nBalance-sheet metrics show a contraction largely linked to fair-value movements in equity holdings:\n• Total assets declined 3.48% to RMB 5.58 billion.\n• Owners’ equity attributable to shareholders fell 2.93% to RMB 4.63 billion, translating into net assets per share of RMB 17.98, versus RMB 18.50 at the beginning of the period.\nManagement attributes the robust profit growth mainly to stronger sales performance and dividend contributions, while marking-to-market adjustments on equity investments weighed on net asset values. The figures are preliminary and subject to audit; final results will be disclosed in Lisheng Pharmaceutical’s 2025 annual report.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1135591771","isCrawlerRequest":true}